1 Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018 Feb;25(2):215–37.
2 Achtnichts L CA, Czaplinski A, Derfuss T, du Pasquier R, Findling O, Gobbi C, Hoepner R, Kamber N, Kamm CP, Kuhle J, Lalive P, Lutterotti A, Martin R, Müller S, Papadopouplou A, Pot C, Salmen A, Schippling S, Zecca C, in cooperation with the scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. Specific aspects of Immunotherapy for Multiple Sclerosis in Switzerland: a structured commentary. Clinical and Translational Neuroscience. 2018.
3 Arzneimittel-Kompendium der Schweiz. Lemtrada Fachinformation. [updated 09.04.201910.09.2018]; Available from:
https://www.compendium.ch/mpro/mnr/26265/html/de.
4 Swissmedic. DHPC – Lemtrada (Alemtuzumab), Einschränkung der Anwendung bei Multipler Sklerose aufgrund von Sicherheitsbedenken, 14.06.2019. [03.07.2019]; Available from:
https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-lemtrada_alemtuzumab.html.
5 Bundesamt für Gesundheit. Lemtrada Spezialitätenliste. [updated 09.04.201910.09.2018]; Available from:
http://www.spezialitätenliste.ch/ShowPreparations.aspx?searchType=ATCCODE&searchValue=L04AA34.
6 European Medicines Agency. Lemtrada Zusammenfassung der Merkmale des Arzneimittels. [updated 09.04.201910.09.2018]; Available from:
http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf.
7 European Medicines Agency. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing, 12.04.2019. [03.07.2019]; Available from:
https://www.ema.europa.eu/en/news/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing.
8 Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1819–28.
9 Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829–39.
10 Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018 May;17(5):467–80.
11 Bundesamt für Gesundheit. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung. [updated 09.04.201914.09.2018]; Available from:
https://www.admin.ch/opc/de/classified-compilation/19950275/index.html.
12 Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012 Jun;47(6):770–90.
13 Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017 Apr 1;74(4):459–69.
14 Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017 Jul;13(7):391–405.
15 Arneimettel-Kompendium der Schweiz. Mavenclad Fachinformation. [03.07.2019]; Available from:
https://compendium.ch/mpro/mnr/29078/html/de.
16 Bundesamt für Gesundheit. Mavenclad Späzialitätenliste. [03.07.2019]; Available from:
http://www.xn--spezialittenliste-yqb.ch/ShowPreparations.aspx.
17 European Medicines Agency. Mavenclad Zusammenfassung der Merkmale des Arzneimittels. [03.07.2019]; Available from:
https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_de.pdf.
18 European Medicines Agency. Mavenclad Zusammenfassung der Merkmale des Arzneimittels. [updated 09.04.201910.09.2018]; Available from:
http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/004230/WC500234561.pdf.
19 Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416–26.
20 European Medicines Agency. EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage. [11.09.2018]; Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zinbryta_20/European_Commission_final_decision/WC500238074.pdf.
21 Swissmedic. DHPC – ZINBRYTA® (Daclizumab beta) Berichte über immunvermittelte Enzephalitis, einschliesslich Anti-NMDA-rezeptorvermittelte Enzephalitis, mehrere Monate nach Absetzen. [11.09.2018]; Available from:
https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-zinbryta_dacclizumabbeta.html.
23 Arzneimittel-Kompendium der Schweiz. Gilenya Fachinformation. [updated 09.04.201911.09.2018]; Available from:
https://compendium.ch/mpro/mnr/22119/html/de.
24 Bundesamt für Gesundheit. Gilenya Spezialitätenliste. [updated 09.04.201911.09.2018]; Available from:
http://www.spezialitätenliste.ch/ShowPreparations.aspx?searchType=ATCCODE&searchValue=L04AA27.
25 European Medicines Agency. Gilenya Zusammenfassung der Merkmale des Arzneimittels. [updated 09.04.201921.01.2019]; Available from:
http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf.
26 Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
27 Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–56.
28 Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402–15.
29 Chitnis T, Arnold DL, Banwell B, Bruck W, Ghezzi A, Giovannoni G, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med. 2018 Sep 13;379(11):1017–27.
30 Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018 May 15;90(20):e1815-e21.
31 Mills EA, Mao-Draayer Y. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler. 2018 Jul;24(8):1014–22.
32 Carpenter AF, Goodwin SJ, Bornstein PF, Larson AJ, Markus CK. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections? Mult Scler. 2017 Feb;23(2):297–9.
33 Grebenciucova E, Reder AT, Bernard JT. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord. 2016 Sep;9:158–62.
34 Lalive PH, Roth S, Du Pasquier R. Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2019 Jan 15;92(3):151.
35 Arzneimittel-Kompendium der Schweiz. Ocrevus Fachinformation. [11.09.2018]; Available from:
https://www.compendium.ch/mpro/mnr/28205/html/de.
36 Bundesamt für Gesundheit. Ocrevus Spezialitätenliste. (11.09.2018).
37 European Medicines Agency. Ocrevus Zusammenfassung der Merkmale des Arzneimittels. [10.09.2018]; Available from:
http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/004043/WC500241124.pdf.
38 Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221–34.
39 Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–20.
40 Dalla Torre Di Sanguinetto S, Heinonen E, Antonov J, Bolte C. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA. Ther Innov Regul Sci. 2018 Jan 1:2168479018764660.